Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
ONTARGET - Ongoing telmisartan alone and in combination with ramipril global endpoint trial und TRANSCEND - Telmisartan randomized assessment study in ACE-I intolerant subjects with cardiovascular disease (30 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 4: ONTARGET - background Abb. 5: ONTARGET - background Abb. 6: ONTARGET - from HOPE to ONTARGET Aktuelles Bild - Abb. 7: ONTARGET - the HOPE study Abb. 8: HOPE study results: primary end point Abb. 9: HOPE study results: secondary end point Abb. 10: ONTARGET - Rationale Zum letzten Bild
Abbildung 7: ONTARGET - the HOPE study
The HOPE study was a double-blind, randomized, placebo-controlled trial, conducted by 267 study centres in 19 countries. [7] Inclusion criteria for the study were a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes plus at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low high-density lipoprotein cholesterol levels, cigarette smoking, or documented microalbuminuria). Exclusion criteria were known heart failure with an ejection fraction below 0.40, existing ACE inhibitor or vitamin E medication, uncontrolled hypertension or overt nephropathy, or a history of myocardial infarction or stroke within 4 weeks of study initiation. 9297 patients underwent randomization, 4645 to treatment with ramipril and 4652 to placebo. Among the total patients randomized, 2480 were women, 5128 were at least 65 years of age, 8162 had cardiovascular disease, 4355 had hypertension, and 3577 had diabetes. The mean follow-up period for the study was 4.5 years. 7. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153.
 
ONTARGET - the HOPE study
Vorheriges Bild Nächstes Bild   


Abbildung 7: ONTARGET - the HOPE study
The HOPE study was a double-blind, randomized, placebo-controlled trial, conducted by 267 study centres in 19 countries. [7] Inclusion criteria for the study were a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes plus at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low high-density lipoprotein cholesterol levels, cigarette smoking, or documented microalbuminuria). Exclusion criteria were known heart failure with an ejection fraction below 0.40, existing ACE inhibitor or vitamin E medication, uncontrolled hypertension or overt nephropathy, or a history of myocardial infarction or stroke within 4 weeks of study initiation. 9297 patients underwent randomization, 4645 to treatment with ramipril and 4652 to placebo. Among the total patients randomized, 2480 were women, 5128 were at least 65 years of age, 8162 had cardiovascular disease, 4355 had hypertension, and 3577 had diabetes. The mean follow-up period for the study was 4.5 years. 7. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung